| Host: |
Mouse/Mouse |
| Applications: |
ELISA |
| Reactivity: |
Human |
| Note: |
FOR SCIENTIFIC EDUCATIONAL RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR OTHER MEDICAL APPLICATIONS. |
| Short Description: |
This PD-L1 antibody pair contains complimentary capture and detection antibodies, which work together under the principals of the Sandwich ELISA. |
| Conjugation: |
Unconjugated/Biotin |
| Formulation: |
Capture Buffer: PBS with 0.04% Proclin 300; 50% glycerol; pH 7.5.Detection Buffer: PBS with 0.04% Proclin 300; 1% protective protein; 50% glycerol; pH 7.5. |
| Purification: |
Capture Purification: Protein A or G.Detection Purification: Protein A or G. |
| Concentration: |
0.5 mg/mL |
| Storage Instruction: |
Store at-20°C for long term, and avoid freeze-thaw cycles. |
| Determination Method: |
Colormetric |
| Gene Symbol: |
CD274 |
| Gene ID: |
29126 |
| Uniprot ID: |
PD1L1_HUMAN |
| Immunogen: |
Capture immunogen: Recombinant Human PD-L1 protien.Detection Immunogen: Recombinant Human PD-L1 protien. |
| Sample Type: |
Serum, plasma and other biological fluids |
| Post Translational Modifications | Ubiquitinated.STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. Ubiquitinated by MARCHF8.leading to degradation. Deubiquitinated by USP22.leading to stabilization. |
| Function | Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. |
| Protein Name | Programmed Cell Death 1 Ligand 1Pd-L1Pdcd1 Ligand 1Programmed Death Ligand 1Hpd-L1B7 Homolog 1B7-H1Cd Antigen Cd274 |
| Database Links | Reactome: R-HSA-389948Reactome: R-HSA-9701898 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinEarly Endosome MembraneRecycling Endosome MembraneNucleusAssociates With Cmtm6 At Recycling EndosomesWhere It Is Protected From Being Targeted For Lysosomal DegradationTranslocates To The Nucleus In Response To Hypoxia Via Its Interaction With Phosphorylated Stat3Isoform 1: Cell MembraneIsoform 2: Endomembrane SystemIsoform 4: Secreted |
| Alternative Antibody Pair Names | Programmed Cell Death 1 Ligand 1 antibody pairPd-L1 antibody pairPdcd1 Ligand 1 antibody pairProgrammed Death Ligand 1 antibody pairHpd-L1 antibody pairB7 Homolog 1 antibody pairB7-H1 antibody pairCd Antigen Cd274 antibody pairCD274 antibody pairB7H1 antibody pairPDCD1L1 antibody pairPDCD1LG1 antibody pairPDL1 antibody pair |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
